Clinical Trial Update: Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

AbbVie’s Phase 2 trial evaluating oral NX-13 for moderate to severe ulcerative colitis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• NX-13

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED